NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT02292979,Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hodgkin Lymphoma.,https://clinicaltrials.gov/study/NCT02292979,BREACH,COMPLETED,"This study aims to evaluate the efficacy of brentuximab vedotin + AVD combination (doxorubicine, vinblastine, dacarbazine) in patients with Hodgkin lymphoma stage I / II with an unfavorable diagnosis, assessed by the negativity of PET (positron emission tomography ) after two cycles of chemotherapy.",NO,Hodgkin Lymphoma,DRUG: Doxorubicin|DRUG: Bleomycin|DRUG: Vinblastine|DRUG: Dacarbazine|DRUG: Brentuximab Vedotin,"PET2 assessment, Assessment of PET after two cycles according to the five-point scale Deauville criteria (Negative = 1, 2, 3 and Positive = 4, 5), based on central review., 8 weeks","Complete response (CR) rate, according to Cheson 2007 criteria, 16 weeks|Progression free survival (PFS), Survival without disease progression, 5 years|Overall survival (OS), 5 years",,The Lymphoma Academic Research Organisation,"Millennium Pharmaceuticals, Inc.",ALL,ADULT,PHASE2,170,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,BREACH,2015-03,2016-12,2022-06-02,2014-11-18,,2022-08-19,"ZNA Middelheim, Antwerpen, Belgium|ZNA Stuivenberg, Antwerpen, Belgium|A.Z. Sint Jan AV, Brugge, Belgium|Institut Jules Bordet, Bruxelles, Belgium|UCL Louvain Saint Luc, Bruxelles, Belgium|Grand Hôpital de Charleroi, Charleroi, Belgium|Universitair Ziekenhuis Antwerpen, Edegem, Belgium|U.Z. Leuven - Campus Gasthuisberg, Leuven, Belgium|CHU de Liege, Liege, Belgium|AZ Delta - Campus H. Hartziekenhuis, Roeselare, Belgium|CHU Dinant Godinne, Yvoir, Belgium|University Hospital Rebro, Zagreb, Croatia|Rigshospitalet, Copenhagen, Denmark|CHU d'Amiens, Amiens, France|CHU d'Angers, Angers, France|CH de Annecy, Annecy, France|CHU Jean Minjoz, Besançon, France|CH de Bourg en Bresse, Bourg en Bresse, France|Centre François Baclesse, Caen, France|CHU de Caen, Caen, France|CH de Chalon sur Saône, Chalon sur Saône, France|CH de Chambéry, Chambéry, France|Hôpital Antoine Béclère, Clamart, France|CHU de Clermont-Ferrand, Clermont-Ferrand, France|CH Sud Francilien de Corbeil, Corbeil Essonnes, France|CHU Henri Mondor, Créteil, France|CHU de Dijon, Dijon, France|CHU de Grenoble, Grenoble, France|CH La Rochelle, La Rochelle, France|Centre Hospitalier de Versailles - André Mignot, Le Chesnay, 78157, France|CHRU de Lille - Hôpital Claude Hurriez, Lille, 59037, France|CHU de Limoges, Limoges, France|Centre Léon Bérard, Lyon, France|Institut Paoli Calmettes, Marseille, France|CH de Meaux, Meaux, France|CHR de Metz, Metz, France|CHU de Montpellier - Saint Eloi, Montpellier, France|CHU de Mulhouse, Mulhouse, France|CHU Nancy Brabois, Nancy, France|CHU Hôtel Dieu Nantes, Nantes, France|CHU de Nîmes, Nîmes, France|Hôpital Necker, Paris, 75743, France|Hôpital de la Pitié Salpétrière, Paris, France|Hôpital Saint Antoine, Paris, France|Hôpital Saint Louis, Paris, France|Centre François Magendie, Pessac, France|Centre Hospitalier Lyon Sud, Pierre Bénite, 69495, France|CHU Robert Debré, Reims, France|CHU Pontchaillou, Rennes, France|CH de Roubaix, Roubaix, France|Centre Henri Becquerel, Rouen, France|Institut de Cancérologie de Loire, Saint Priest en Jarez, France|CHU de Strasbourg, Strasbourg, France|CHU de Toulouse, Toulouse, France|CHU Bretonneau, Tours, 37044, France|Institut Gustave Roussy, Villejuif, France|Academisch Medisch Centrum - Universiteit van Amsterdam, Amsterdam, Netherlands|Antoni Van Leeuwenhoekziekenhuis, Amsterdam, Netherlands|Amphia Ziekenhuis, Breda, Netherlands|Reinier De Graaf Gasthuis, Delft, Netherlands|University Medical Center Groningen, Groningen, Netherlands|Leiden University Medical Centre, Leiden, Netherlands|Radboud University Medical Center Nijmegen, Nijmegen, Netherlands|Erasmus MC Cancer Institute - location Daniel den Hoed, Rotterdam, Netherlands|Erasmus MC, Rotterdam, Netherlands",
